Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Multiple Myeloma 1

Interventions

pembrolizumab 78 Cyclophosphamide 55 Specimen Handling 53 Carboplatin 49 fludarabine 44 Nivolumab 42 Magnetic Resonance Spectroscopy 42 Gemcitabine 37 Biopsy 37 Bevacizumab 34 Dexamethasone 31 venetoclax 27 Paclitaxel 26 Injections 25 Docetaxel 25 atezolizumab 24 Cisplatin 24 Pemetrexed 23 Ipilimumab 22 Capecitabine 21 Temozolomide 19 abemaciclib 18 Rituximab 18 Oxaliplatin 18 Lenalidomide 18 Fulvestrant 18 Cetuximab 18 Azacitidine 17 Vincristine 15 Fluorouracil 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Clarithromycin × 90 days × Clear all

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡